Evidence map›Paper›PMID 41580988›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

p16

Koji Nishikawa, Teh-Wei Wang, Satoshi Kawakami, Shota Tanimoto, Kiyoshi Yamaguchi, Taketomo Kido, Masamichi Kimura, Tsunekazu Hishima, Yuki T Okamura, Satotaka Omori and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. CombinedFrontiers in pharmacology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Koji NishikawaDivision of Cancer Cell Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Teh-Wei WangDivision of Cancer Cell Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Satoshi KawakamiDivision of Cancer Cell Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Shota TanimotoDivision of Cancer Cell Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kiyoshi YamaguchiDivision of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Taketomo KidoLaboratory of Cell Growth and Differentiation, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan.
Masamichi KimuraDepartment of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Tsunekazu HishimaDepartment of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Yuki T OkamuraDivision of Cancer Cell Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Satotaka OmoriIntegrated Biosciences, Redwood City, California, USA.
Takumi IritaniProject Division of Generative AI Utilization Aging Cells, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Toshikaze ChibaProject Division of Generative AI Utilization Aging Cells, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Takehiro JimboProject Division of Generative AI Utilization Aging Cells, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Michio KatanoProject Division of Generative AI Utilization Aging Cells, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kansuporn KamatakiProject Division of Generative AI Utilization Aging Cells, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Ryoichi YokoyamaProject Division of Generative AI Utilization Aging Cells, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Eigo ShimizuDivision of Health Medical Intelligence, Human Genome Center, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kiminori KimuraDepartment of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Satoshi YamzakiDivision of Cell Regulation, Center of Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Seiya ImotoDivision of Health Medical Intelligence, Human Genome Center, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yoichi FurukawaDivision of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Atsushi MiyajimaLaboratory of Cell Growth and Differentiation, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan.
Yoshikazu JohmuraDivision of Cancer and Senescence Biology, Cancer Research Institute, Kanazawa University, Kakuma, Kanazawa, Japan.
Makoto NakanishiDivision of Cancer Cell Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-6707-3584

Funding

Japan Agency for Medical Research and Development JP20ck010655hJapan Agency for Medical Research and Development JP20gm5010001sJapan Agency for Medical Research and Development JP223fa627001Japan Agency for Medical Research and Development JP23gm1410013hJapan Agency for Medical Research and Development JP23zf0127003hJapan Agency for Medical Research and Development JP24gm6410014h0004Japan Agency for Medical Research and Development JP24wm0625306h0001Japan Agency for Medical Research and Development JP25bm1123019h0003Japan Agency for Medical Research and Development JP25fk0210151h0002MEXT/Japan Society for the Promotion of Science KAKENHI JP19H05740MEXT/Japan Society for the Promotion of Science KAKENHI JP20H00514MEXT/Japan Society for the Promotion of Science KAKENHI JP20K21497MEXT/Japan Society for the Promotion of Science KAKENHI JP23H00391MEXT/Japan Society for the Promotion of Science KAKENHI JP23H03834MEXT/Japan Society for the Promotion of Science KAKENHI JP23H03835MEXT/Japan Society for the Promotion of Science KAKENHI JP23K27376MEXT/Japan Society for the Promotion of Science KAKENHI JP24K22049MEXT/Japan Society for the Promotion of Science KAKENHI JP25K18870MEXT/Japan Society for the Promotion of Science KAKENHI JPJS00420230006(J-PEAKS)MEXT/Japan Society for the Promotion of Science KAKENHI JPMXP1323015484(CURE)Princess Takamatsu Cancer Research Fund
6 · The paper itself

Abstract

As organs undergo the process of aging, they exhibit signs of progressive fibrosis, a hallmark of aging that is observed in various organs, including the liver, kidneys, and lungs. Liver fibrosis is a particularly deleterious outcome of the healing processes that occur during the repair of chronic liver injury. It is widely accepted that the majority of these injuries are initially triggered by hepatocytes. Indeed, elderly patients have been shown to be more prone to developing liver fibrosis following hepatic injury. However, the mechanisms by which aging promotes fibrotic processes remain to be elucidated. The preceding observation, indicating a robust correlation between the severity of fibrosis in human cirrhotic patients and the population of hepatocytes expressing elevated levels of p16

Indexed as

Cyclin-Dependent Kinase Inhibitor p16HepatocytesLiver CirrhosisAnimalsCellular SenescenceDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLSignal TransductionCyclin-Dependent Kinase Inhibitor p16cellular senescenceLIFR pathwayliver fibrosis

Identifiers

PMID41580988
PMCPMC13042423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.